Cognition and NEDA in MS: A 2-Year Follow-Up
Author Information
Author(s): E. Leveraro, M. Cellerino, C. Lapucci, M. Dighero, L. Nasone, T. Sirito, D. Boccia, N. Cavalli, G. Bavestrello, A. Uccelli, G. Boffa, M. Inglese
Primary Institution: University of Genoa and IRCCS Ospedale Policlinico San Martino
Hypothesis
Efficient treatment-induced disease control could prevent cognitive worsening in MS patients.
Conclusion
Early disease activity control may yield significant benefits in cognitive performance for MS patients, especially those with low baseline disability.
Supporting Evidence
- 78% of patients maintained NEDA-3 status over 24 months.
- 12% of patients improved in cognitive tests like SDMT.
- Lower EDSS was an independent predictor of cognitive improvement.
Takeaway
This study shows that treating MS patients early can help them think better, even if they seem stable.
Methodology
101 MS patients were assessed using BICAMS, EDSS, and HADS at baseline and after 24 months to evaluate cognitive changes.
Potential Biases
Potential bias due to the exclusion of patients with other neurological or psychiatric disorders.
Limitations
The study had a relatively small sample size and did not assess the impact of fatigue on cognitive performance.
Participant Demographics
Mean age 40.45 years, 61.4% female, 81.2% with Relapsing-Remitting MS.
Statistical Information
P-Value
0.003
Confidence Interval
90%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website